Rainmed Medical Limited (HKG: 2297), a China‑based cardiovascular precision‑diagnosis company, released its unaudited interim results for the six months ended 30 June 2026, reporting revenue of RMB14.7 million, up approximately 41% year‑on‑year from RMB10.4 million, driven primarily by sales of the FlashPressure caFFR pressure transducer. Gross profit rose 82.4% to RMB9.3 million, with gross margin expanding to 63.2% from 49.2%, while the loss for the period narrowed ~31% to RMB23.0 million (1H 2025: RMB33.3 million) on broad cost discipline across R&D, selling, and administrative expenses.
Financial Performance – 1H 2026 vs. 1H 2025
| Metric | 1H 2026 | 1H 2025 | Change |
|---|---|---|---|
| Revenue | RMB14.7 m | RMB10.4 m | +41 % |
| Gross Profit | RMB9.3 m | RMB5.1 m | +82.4 % |
| Gross Margin | 63.2 % | 49.2 % | +14.0 ppt |
| R&D Expenses | RMB4.9 m | RMB6.4 m | −22.7 % |
| Selling Expenses | RMB11.3 m | RMB15.1 m | −25.1 % |
| G&A Expenses | RMB16.8 m | RMB20.6 m | −18.5 % |
| Loss for the Period | RMB23.0 m | RMB33.3 m | ~31 % narrower |
| Loss per Share (basic & diluted) | RMB0.02 | RMB0.03 | – |
| Dividend | None declared | None declared | – |
Revenue by product (RMB’000): FlashPressure caFFR pressure transducer 11,908 (1H25: 6,781 — the core growth engine); coronary artery cutting balloon 1,388 (new — first revenue after inclusion in the national centralized bulk procurement (VBP) program); IVD products 1,134 (1H25: 2,297); FlashAngio caIMR System 112; FlashAngio caFFR System 75; installation & training services 55.
Balance Sheet & Liquidity Snapshot
- Cash & Cash Equivalents: RMB7.8 m at 30 Jun 2026 (vs. RMB14.4 m at 31 Dec 2025), supplemented by RMB121.3 m in low‑risk USD wealth‑management products (FVTPL).
- Leverage: Outstanding borrowings of RMB181.1 m (bank borrowings RMB150.0 m); gearing ratio 54.9%; unutilized bank facilities of RMB20.0 m. Bank loans are secured by land use rights.
- Capex Push: Net cash used in investing activities of RMB146.7 m, mainly RMB160.3 m of property, plant & equipment purchases for the Group’s industrial park (contracted capital commitments of RMB23.1 m remaining); financed by RMB157.1 m net inflow from financing activities, primarily new bank and other borrowings of RMB165.6 m.
- Working Capital: Net current assets rose to RMB116.7 m from RMB23.9 m at year‑end 2025.
Core Products & Commercialization
- caFFR System (FlashAngio + FlashPressure): Angiography‑based, less‑invasive coronary physiological assessment — a NMPA Class III device with >95 % diagnostic accuracy and a <5‑minute workflow; a leading domestic FFR product. Holds CE Mark (Sep 2019), NMPA approval (Dec 2019), plus Australia TGA, Brazil ANVISA, and Korea approvals.
- caIMR System: The world’s first less‑invasive IMR system approved for commercialization (NMPA Apr 2023; ANVISA Jan 2024; Korea MOHW Jun 2024), with published diagnostic accuracy of 93.8 %, sensitivity 95.1 %, specificity 93.1 %.
- Distribution Network (as of 30 Jun 2026): 141 domestic distributors covering 291+ hospitals across 21 provinces, 4 autonomous regions and 4 municipalities; Core Products installed at 790+ hospitals and performed at 1,500+ hospitals; procurement approval completed at 750+ hospitals.
- Reimbursement: Patient charging price of RMB10,200–12,000 for caFFR consumables set in 33 provinces/regions, with 24 provinces/regions (incl. Shanghai, Guangdong, Chongqing, Henan) covering it under medical insurance; caIMR reimbursement inclusion is being actively pursued.
- New Revenue Stream: The coronary cutting balloon, included in national VBP, began contributing revenue (~RMB1.39 m) with volumes expected to rise as hospital coverage expands.
- IVD & Manufacturing: 85 Class II IVD registration certificates (via the Tianjin Yuehekang acquisition); three manufacturing sites (~7,962 sq.m) with annual capacity of 11,375 consoles and 1,130,765 pressure transducers.
Pipeline & Intellectual Property
- Indication Expansion: A Phase III post‑registration trial is in progress to extend caFFR into acute STEMI, acute NSTEMI and HFpEF (milestone expected 2026); a Phase III trial for caIMR in post‑revascularization STEMI is slated for initiation (2029).
- Strategic Refocus: The Group has discontinued registration programs for the Flash Robot navigation system, Flash RDN System, and the intelligent angiographic injection system, concentrating resources on the commercial caFFR/caIMR franchise, IVD, and VBP‑covered interventional consumables.
- IP Portfolio: 213 granted patents (186 China, 7 US, 4 Europe, 16 Japan), 61 pending applications, 341 registered trademarks; 208 full‑time employees as of 30 Jun 2026.
Market Impact & Outlook
- Margin Inflection: The combination of a high‑margin disposable transducer mix, tighter cost control, and VBP‑driven balloon volumes lifted gross margin by 14 percentage points, materially improving the path toward breakeven.
- Policy Tailwind: National centralized procurement and expanding provincial medical‑insurance coverage are accelerating hospital access for the company’s consumables — a structural demand driver into 2H 2026.
- Management Guidance: Despite stricter device compliance and a volatile market, management targets deeper penetration in Mainland China and “healthy growth and high‑quality development” for full‑year 2026, while continuing to invest in the Suzhou industrial park to consolidate manufacturing and R&D.
- Watch Items: A thin cash balance (RMB7.8 m) against RMB181.1 m of borrowings keeps liquidity management — including the RMB121.3 m wealth‑management portfolio — central to the story; board changes (resignation of Mr. Wang Lin and appointment of Mr. Lu Xun as non‑executive Director, effective 4 Sep 2026) were flagged as the only material subsequent event.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Rainmed Medical’s revenue trajectory, reimbursement expansion, clinical trial milestones, capital expenditure plans, and liquidity expectations for 2026 and beyond. Actual results may differ due to risks including centralized procurement policy changes, reimbursement approvals, clinical and regulatory outcomes, competition, borrowing costs, and cash‑flow constraints. Interim figures are unaudited.-Fineline Info & Tech
